All stock lists
Zura Bio Limited (NASDAQ:ZURA)
US · Delayed Price · Currency is USD
Also listed: 94E.FHealthcare · Biotechnology
0.96-3.13 (-76.55%)
Market cap
$92.4M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 21, 2023
Website
Insider Score
––Not scored
ZURA Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From ZURA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$93.5M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $187.7M
- Debt / equity
- 0.00
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $191.6M
- Current liabilities
- $17.0M
- Current ratio
- 11.29
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$81.6M
- Free cash flow
- -$81.7M
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 127.7M
- Share growth (1y)
- 35.1%
- Cash runway
- 28 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ZURA Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 9.28 M | 8.62 M | 10.75 M | 7.46 M | 7.57 M | 9.36 M |
| R&D Expense | 19.49 M | 20.71 M | 14.75 M | 10.96 M | 11.95 M | 8.70 M |
| Operating Expenses | 28.77 M | 29.32 M | 25.50 M | 18.41 M | 19.52 M | 18.06 M |
| Operating Income | -28.77 M | -29.32 M | -25.50 M | -18.41 M | -19.52 M | -18.06 M |
| Pretax Income | -27.05 M | -26.39 M | -24.22 M | -17.18 M | -18.04 M | -15.99 M |
| Tax Provision | -1.22 M | -81.00 K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -25.82 M | -26.30 M | -24.22 M | -17.18 M | -18.04 M | -15.99 M |
| EPS (Basic) | -0.20 | -0.21 | -0.22 | -0.49 | -0.21 | -0.17 |
| EPS (Diluted) | -0.20 | -0.21 | -0.22 | -0.49 | -0.21 | -0.17 |
| Shares Outstanding | 127.71 M | 126.80 M | 112.22 M | 94.16 M | 94.56 M | 94.29 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.